Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Nutranomics, Inc.
DRAPER, Utah, Oct. 30, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to report that Linna Ltd. of Kanagawa, Japan ("Linna") has finalized a plan to include the patented AES™ (Assimilation Enhancing System) enzyme blend from Nutranomics in a premium dog and cat food line. This marks the first time that the AES™ has been incorporated into the formulation of a pet food product.
The Company anticipates that AES™ will be included in the formulation of the Cupurera brand of high quality pet food products owned by Linna. The concept behind the Cupurera dog and cat product line is to provide human quality ingredients for superior pet food. The Cupurera pet food line is advertised as "The Perfect Natural Pet Food" and includes probiotics and enzymes to improve digestion and nutrient absorption, and is gluten free.
"Since most dog and cat food products are fully cooked, putting the proper balanced enzymes back into the food to improve digestion and nutrient absorption was a good idea not only from a Cupurera marketing perspective, but most importantly for the health of our beloved pets," explained Nutranomics' CEO Dr. Tracy K. Gibbs. "The planned introduction of our patented AES™ enzyme blend into a complete pet food line has led Nutranomics into an entirely new growing industry with many new high demand product opportunities to potentially develop in the future."
According to American Pet Products Association (APPA), which collects industry statistics from various market research sources, it has been estimated that in 2013, $55.53 billion will be spent on pets in the United States alone, including $21.26 billion on pet food, $13.21 billion on supplies and OTC medicines, and $14.21 on veterinarian care.
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at firstname.lastname@example.org or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include the Company's plan to execute and accelerate its global sales and marketing plans. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
©2012 PR Newswire. All Rights Reserved.